Meanwhile, the overall final complete remission rate after two cycles of chemotherapy of AML patients with different immunophenotype (MPAL, Ly+AML, and Ly−AML) had no statistical differences in the same genetic background.
Three months after the final administration, complete remission was found in one patient (3%), partial remission in 12 (35%), stable disease in 14 (41%) and progressive disease in seven (21%), including three patients who died during the treatment period.
Additional subgroup analyses were run in 1424 patients with and in 1257 subjects without corticosteroid therapy, and in 1115 patients with successful therapy as indicated by DAS28ESR defined remission at final observation.
In conclusion, over the last decade, treatment has been moving from showing any efficacy at all in patients with active SpA to earlier treatment with the final aim of inducing remission and preventing structural damage.
Among these, 164 had documented a remission but had final vital status "Died from Disease", indicating that a relapse had taken place.
Moreover, a considerable amount of evidence has been accumulated suggesting that normalization of the HPA system might be the final step necessary for stable remission of the disease [ 24].
In total, 36 patients were in remission at the final visit of the double-blind phase and were eligible to enter the 6-month treatment-free follow-up phase.
Overall, 285 of 345 (82.6%) participants met criteria for clinical response and 227 of 345 (65.8%) participants met criteria for symptomatic remission at their final study visit (ie, end of study/or early termination [ET]).
Complications such as pin site osteitis did not influence the final outcome with many patients reporting remission of pain from the hip.
The third phenotype was remission, defined as a final QIDS-SR score ≤5.
